ClinicalTrials.gg
RecruitingNCT06651801Updated Oct 14, 2026

Feasibility and Acceptability of Group Medical Visits for Anxiety and Depression

An interventional study of Group Medical Visits in Mental Health Care, Anxiety and Depression and Pilot Study, sponsored by University of Manitoba. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Primary conditionDepressionRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depression
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depression.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Manitoba · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Oct 14, 2026Now RecruitingFirst site in Canada+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Depression by University of Manitoba — 6 open to participants now, 7 under way, none of them phase 3. Depression · University of Manitoba.

Planned enrollment
19th of 22
20 · median 56
Started
2025
with 4 others
No phase
21 of 23
5 open now
Registered
18th of 23
by date

Among the 23 studies in Depression by University of Manitoba, this one is the 19th largest by planned enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2025, is one of 21 with no phase, and was the 18th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

6 of the 23 studies in Depression by University of Manitoba are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Depression by University of Manitoba, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the feasibility and acceptability of the intervention, Group Medical Visits (GMVs), for patients with depression and anxiety. It also aims to get some initial information on the effectiveness of GMVs on reducing depression and anxiety scores, which will help inform power calculations for a future larger randomized controlled trial (RCT). The main question it aims to answer is:

  • Are GMVs feasible and acceptable to patients with depression and anxiety?

This study consists of a pilot RCT with an intervention and control arm. At enrollment, participants will be randomized to the intervention group, 6 months of GMVs, or to the control group, which consists of "standard client services". For the GMV group, participants will engage in a biweekly virtual group that is similar to a standard psychiatric follow-up. Participants in the control group will receive standard care after a psychiatric assessment, which includes follow-up with their primary care provider (family physician or nurse practitioner), individual psychiatric care if suggested by the psychiatrist who did their psychiatric assessment, and/or a referral to publicly funded therapy groups if interested.

03

Conditions studied

  • Mental Health Care
  • Anxiety and Depression
  • Pilot Study

Browse trials for

Keywords

  • Group Medical Visits
  • Anxiety
  • Depression
  • Shared Medical Appointments
  • Pilot Study
04

In context

Depression Reclassified

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

This study's planned enrollment of 20 is below the median of 81 across 7,089 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

University of Manitoba is the lead sponsor of 555 studies on the registry; 88 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.

Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients who are looking for longitudinal psychiatric follow-up after a one-time consult or discharge from a mental health program.
  • Primary mental health issue is an anxiety or depressive disorder.
  • Able to commit to a virtual biweekly group on Tuesdays from 2:30-4PM.
  • Able to do virtual group from a private location with camera access.
  • Live in community in Manitoba and plan to stay for a 6-month period.

Exclusion criteria

Exclusion Criteria:

  • Patients with confirmed Bipolar 1 or 2 Disorder.
  • Patients who already have longitudinal care with a psychiatrist.
  • Received ECT treatment within past 6 months.
  • Concern about safety of other group members/facilitators if this patient were to join.
  • Any co-morbidity/behaviour that would significantly impact ability to participate in the group. For example:
  • Severe substance use disorder.
  • Significant PTSD or OCD symptoms that would impact group participation.
  • Severe personality disorder.
  • Current psychotic symptoms.
  • Moderate to severe intellectual disability or neurocognitive disorder.
  • Current significant eating disorder symptoms.
  • Self-harm behaviour requiring medical/psychiatric attention or suicide attempt within the past 6 months.
06

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • No intervention
    Standard client services

    Participants will follow-up with their primary care provider (family physician or nurse practitioner).

  • Experimental
    Virtual outpatient care

    Behavioral: Group Medical Visits

Interventions

  • BehavioralGroup Medical Visits

    Group medical visits occur every 2 weeks virtually (via Zoom) for 6 months. Each group consists of 45 minutes of group time and 5 minute individual check-in appointments. The group time consists of psychoeducation, group support, and medication follow-up.

07

What researchers measure

Primary outcomes

  1. Client Satisfaction Questionnaire-4 Scale (CSQ-4)

    Includes 4 items that measure client satisfaction. Items are rated on a 4-point scale, with total score ranging from 4 to 16. A higher score indicates higher satisfaction.

    Time frame: Month 3 and month 6 of intervention

  2. Recruitment and Retention Rate

    The investigators will examine the rates of how many participants sign up and are enrolled in the program, along with the drop-out rate throughout the program.

    Time frame: Baseline, during the intervention, through study completion (estimation 9 months)

  3. Primary Care Provider Satisfaction with Psychiatric Care

    The investigators will conduct a telephone survey with the primary care providers (PCPs) of the participants who were randomized to the intervention group. The survey will assess how satisfied the PCPs are with the care that their patient received during the trial. The survey consists of one question assessing overall satisfaction, rated on a 5-item scale from "Very Satisfied" to "Very Dissatisfied", two open ended questions assessing which aspects of care the PCPs were satisfied and not satisfied with, and 5 questions assessing whether they would refer other patients to the program, what benefits were there of having their patient in the program, and what aspects of the program could be improved.

    Time frame: Month 6 of intervention

Secondary outcomes

  1. Patient Health Questionnaire-9 (PHQ-9)

    Includes 9 items assessing depressive symptom severity. Total score ranges from 0 to 20, with a higher score indicating higher symptom severity.

    Time frame: Enrolment (before randomization), baseline (before intervention), month 3, and month 6 of intervention

  2. General Anxiety Disorder-7 (GAD-7)

    Includes 7 items assessing anxiety symptom severity. Total score ranges from 0 to 21, with a higher score indicating higher symptom severity.

    Time frame: Enrolment (before randomization), baseline (before intervention), month 3, and month 6 of intervention

  3. Recovery Assessment Scale 24 (RAS24)

    Includes 24 items assessing personal recovery. Total score ranges from 24 to 120, with higher scores indicating higher levels of recovery.

    Time frame: Enrolment (before randomization), baseline (before intervention), month 3, and month 6 of intervention

  4. Mental Health Quality of Life Questionnaire (MHQoL)

    Consists of 7 domains with 4 items assessing each. Total score ranges from 0 to 21, with higher scores indicating better quality of life.

    Time frame: Enrolment (before randomization), baseline (before intervention), month 3, and month 6 of intervention

08

Study locations

1 of 1 sites recruiting
  • PsycHealth Centre
    Winnipeg, Manitoba R3E 3N4, Canada
    Recruiting
09

References and documents

Publications

  • Kordan C, Hensel J, Sareen J, Moody J, Alsaidi TH, Ayilara OF, Penner-Goeke K. A protocol paper for a pilot randomized controlled trial assessing the feasibility and acceptability of group medical visits for anxiety and depression in adults. Pilot Feasibility Stud. 2026 Apr 29;12(1):86. doi: 10.1186/s40814-026-01802-0. PubMed 42050722 ↗
10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 20 months is close to that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: start Nov 2024 → Apr 2025, primary completion Jun 2025 → Dec 2026 and completion Jul 2025 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2024
First posted
Oct 22, 2024
StartActual
Apr 15, 2025was Nov 2024
Primary completionEst.
Dec 2026was Jun 2025
CompletionEst.
Dec 2026was Jul 2025
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 14, 2026
Sites
1 site added — first site in Canada
Show site
  • PsycHealth Centre · Winnipeg, Canada
Oct 14, 2026
Start date
Nov 2024→Apr 15, 2025 (actual)
Oct 14, 2026
Primary completion
Jun 2025→Dec 2026
Oct 14, 2026
Study completion
Jul 2025→Dec 2026
Oct 14, 2026
Eligibility
2 inclusion criteria edited, 2 added, 2 removed; 6 exclusion criteria edited, 3 added, 2 removed
What changed in the criteria
Inclusion criteria
  • RemovedAdult Central Intake patients (patients referred for psychiatric consultation by their primary care provider) whose primary mental health issue is an anxiety disorder (social anxiety, generalized anxiety, or panic disorder) or depression (major depressive disorder or persistent depressive disorder)
  • RemovedAble to participate in English language group with up to 10 participants
  • AddedAdult patients who are looking for longitudinal psychiatric follow-up after a one-time consult or discharge from a mental health program.
  • AddedPrimary mental health issue is an anxiety or depressive disorder.
  • EditedAble to commit to a virtual biweekly group for about 1on Tuesdays from 2:30-4PM.5 hours each group
  • EditedLive in community in Manitoba and plan to stay for a 6-month period.
Exclusion criteria
  • EditedPatients with confirmed Bipolar 1 or 2 Disorder (even if current episode depression).
  • RemovedPrimary diagnosis of a personality disorder leading to anxiety/depression symptoms (personality disorder traits are not an exclusion criteria)
  • EditedPatients who already have established longitudinal care with a psychiatrist.
  • EditedAny diagnosisco-morbidity/behaviour that would significantly impact ability to participate in the group. For example:
  • RemovedModerate-to-severe substance use disorders (in particular substance use throughout day or inability to attend group without using substances before)
  • AddedSevere substance use disorder.
  • AddedSignificant PTSD or OCD symptoms that would impact group participation.
  • AddedSevere personality disorder.
  • EditedModerate- to- severe intellectual disability or neurocognitive disorder.
  • ChangedBefore Current significant eating disorder symptoms (for example resulting in significant weight loss/malnutrition or that take up a significant part of the day either mentally or physically)Now Current significant eating disorder symptoms.
  • EditedSelf -harm behaviour requiring medical/psychiatric attention or active suicidal ideation/suicide attemptsattempt within the past 6 months.
Oct 14, 2026
Primary outcomes
1 time frame changed, 2 description edited
What changed in the outcomes
  • Time frameClient Satisfaction Questionnaire-4 Scale (CSQ-4)Baseline (before intervention), month 2, month 4, and month 6 of intervention → Month 3 and month 6 of intervention
  • DescriptionPrimary Care Provider Satisfaction with Psychiatric Care: how it is measured was reworded
  • DescriptionRecruitment and Retention Rate: how it is measured was reworded
Oct 14, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42050722 ↗
Oct 14, 2026
Secondary outcomes
4 time frame changed
What changed in the outcomes
  • Time framePatient Health Questionnaire-9 (PHQ-9)Baseline (before intervention), month 2, month 4, and month 6 of intervention → Enrolment (before randomization), baseline (before intervention), month 3, and month 6 of intervention
  • Time frameGeneral Anxiety Disorder-7 (GAD-7)Baseline (before intervention), month 2, month 4, and month 6 of intervention → Enrolment (before randomization), baseline (before intervention), month 3, and month 6 of intervention
  • Time frameRecovery Assessment Scale 24 (RAS24)Baseline (before intervention), month 2, month 4, and month 6 of intervention → Enrolment (before randomization), baseline (before intervention), month 3, and month 6 of intervention
  • Time frameMental Health Quality of Life Questionnaire (MHQoL)Baseline (before intervention), month 2, month 4, and month 6 of intervention → Enrolment (before randomization), baseline (before intervention), month 3, and month 6 of intervention
Oct 14, 2026
Contact
Study contact's phone or email changed: •••3064→•••7949. See the current contact
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Not yet recruiting→Recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42050722 ↗
    1 site added — first site in Canada
    Show site
    • PsycHealth Centre · Winnipeg, Canada
    Start date Nov 2024→Apr 15, 2025 (now actual)
    Primary completion Jun 2025→Dec 2026
    Study completion Jul 2025→Dec 2026
    Eligibility 2 inclusion criteria edited, 2 added, 2 removed; 6 exclusion criteria edited, 3 added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedAdult Central Intake patients (patients referred for psychiatric consultation by their primary care provider) whose primary mental health issue is an anxiety disorder (social anxiety, generalized anxiety, or panic disorder) or depression (major depressive disorder or persistent depressive disorder)
    • RemovedAble to participate in English language group with up to 10 participants
    • AddedAdult patients who are looking for longitudinal psychiatric follow-up after a one-time consult or discharge from a mental health program.
    • AddedPrimary mental health issue is an anxiety or depressive disorder.
    • EditedAble to commit to a virtual biweekly group for about 1on Tuesdays from 2:30-4PM.5 hours each group
    • EditedLive in community in Manitoba and plan to stay for a 6-month period.
    Exclusion criteria
    • EditedPatients with confirmed Bipolar 1 or 2 Disorder (even if current episode depression).
    • RemovedPrimary diagnosis of a personality disorder leading to anxiety/depression symptoms (personality disorder traits are not an exclusion criteria)
    • EditedPatients who already have established longitudinal care with a psychiatrist.
    • EditedAny diagnosisco-morbidity/behaviour that would significantly impact ability to participate in the group. For example:
    • RemovedModerate-to-severe substance use disorders (in particular substance use throughout day or inability to attend group without using substances before)
    • AddedSevere substance use disorder.
    • AddedSignificant PTSD or OCD symptoms that would impact group participation.
    • AddedSevere personality disorder.
    • EditedModerate- to- severe intellectual disability or neurocognitive disorder.
    • ChangedBefore Current significant eating disorder symptoms (for example resulting in significant weight loss/malnutrition or that take up a significant part of the day either mentally or physically)Now Current significant eating disorder symptoms.
    • EditedSelf -harm behaviour requiring medical/psychiatric attention or active suicidal ideation/suicide attemptsattempt within the past 6 months.
    Primary outcomes 1 time frame changed, 2 description edited
    What changed in the outcomes
    • Time frameClient Satisfaction Questionnaire-4 Scale (CSQ-4)Baseline (before intervention), month 2, month 4, and month 6 of intervention → Month 3 and month 6 of intervention
    • DescriptionPrimary Care Provider Satisfaction with Psychiatric Care: how it is measured was reworded
    • DescriptionRecruitment and Retention Rate: how it is measured was reworded
    Secondary outcomes 4 time frame changed
    What changed in the outcomes
    • Time framePatient Health Questionnaire-9 (PHQ-9)Baseline (before intervention), month 2, month 4, and month 6 of intervention → Enrolment (before randomization), baseline (before intervention), month 3, and month 6 of intervention
    • Time frameGeneral Anxiety Disorder-7 (GAD-7)Baseline (before intervention), month 2, month 4, and month 6 of intervention → Enrolment (before randomization), baseline (before intervention), month 3, and month 6 of intervention
    • Time frameRecovery Assessment Scale 24 (RAS24)Baseline (before intervention), month 2, month 4, and month 6 of intervention → Enrolment (before randomization), baseline (before intervention), month 3, and month 6 of intervention
    • Time frameMental Health Quality of Life Questionnaire (MHQoL)Baseline (before intervention), month 2, month 4, and month 6 of intervention → Enrolment (before randomization), baseline (before intervention), month 3, and month 6 of intervention
    Contact Study contact's phone or email changed: •••3064→•••7949. See the current contact
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06651801
Responsible party
Kirsten Penner-Goeke (Principal Investigator, University of Manitoba) — Principal investigator
First posted
Oct 22, 2024
Start date
Apr 15, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 14, 2026

Study contacts

Kirsten Penner-Goeke, MD
Contact
kpennergoeke2@hsc.mb.ca
204-787-7949

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion